Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
· seekingalpha.com
Beam Therapeutics (BEAM) outlook: $1.2B cash runway to mid-2029, pivotal SCD & AATD programs, and attractive valuation—review risks and opportunities now.
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...